Tulane University, New Orleans, LA, USA.
Georgetown University, Washington, DC, USA.
Cell Transplant. 2021 Jan-Dec;30:9636897211035715. doi: 10.1177/09636897211035715.
Traumatic brain injury (TBI) is a pervasive and damaging form of acquired brain injury (ABI). Acute, subacute, and chronic cell death processes, as a result of TBI, contribute to the disease progression and exacerbate outcomes. Extended neuroinflammation can worsen secondary degradation of brain function and structure. Mesenchymal stem cell transplantation has surfaced as a viable approach as a TBI therapeutic due to its immunomodulatory and regenerative features. This article examines the role of inflammation and cell death in ABI as well as the effectiveness of bone marrow-derived mesenchymal stem/stromal cell (BM-MSC) transplants as a treatment for TBI. Furthermore, we analyze new studies featuring transplanted BM-MSCs as a neurorestorative and anti-inflammatory therapy for TBI patients. Although clinical trials support BM-MSC transplants as a viable TBI treatment due to their promising regenerative characteristics, further investigation is imperative to uncover innovative brain repair pathways associated with cell-based therapy as stand-alone or as combination treatments.
创伤性脑损伤 (TBI) 是一种普遍且具有破坏性的获得性脑损伤 (ABI)。TBI 导致的急性、亚急性和慢性细胞死亡过程会促进疾病进展并使预后恶化。持续的神经炎症会加重脑功能和结构的继发性退化。间充质干细胞移植因其具有免疫调节和再生特性,已成为 TBI 治疗的一种可行方法。本文探讨了炎症和细胞死亡在 ABI 中的作用,以及骨髓来源的间充质干细胞/基质细胞 (BM-MSC) 移植作为 TBI 治疗方法的效果。此外,我们还分析了新的研究,这些研究将移植的 BM-MSCs 作为神经修复和抗炎疗法用于 TBI 患者。尽管临床试验支持 BM-MSC 移植作为 TBI 的一种可行治疗方法,因为其具有有前途的再生特性,但仍需要进一步研究以揭示与细胞治疗相关的创新的脑修复途径,无论是作为单独治疗还是联合治疗。